A Houston clinic is telling patients that a July federal advisory vote on six peptides is not clearance to resume treatment, in a press release issued by Houston Regenerative Medicine. The warning is aimed at people who lost access to suppliers earlier this year and read the vote as a green light.

The FDA's Pharmacy Compounding Advisory Committee met July 23 and 24 and voted to recommend six of the seven peptides under review for the agency's 503A Bulks List, the roster of bulk substances compounding pharmacies are permitted to prepare. Those six were BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon. The lone rejection was emideltide.

What the vote actually does

Nothing yet, legally. Before any of the six may be compounded, the FDA has to review the recommendation, publish a proposed rule, take public comment and issue a final rule, and the release says that process has not begun.

The committee's recommendations are advisory only. Worth noting: the panel voted against the assessment of FDA staff scientists, who had advised excluding all seven substances. A separate April action that removed several peptides from the agency's Category 2 list was procedural, tied to withdrawn nominations, and did not authorize compounding either.

Why the timing matters

The gray market that supplied a lot of this material is gone. Science.bio announced a permanent shutdown in January, and Peptide Sciences, described in industry coverage as the largest gray-market research peptide vendor in the United States, closed in March under enforcement pressure.

Patients left mid-protocol have turned to overseas sellers, where material labeled "research use only" carries no requirement for sterility testing, accurate dosing or verified contents. That is the gap the clinic is pointing at, and it is a real one regardless of who is doing the pointing.

Read the source, not the headline

"A recommendation is not a rule, and a rule is not approval," said Andrew Hong, M.D., a physician at the practice. Founder Joel Cherdack, D.C., said the people he worries about are those who stopped a protocol in the spring and have been waiting for a headline exactly like this one.

This is a clinic press release, and it has a commercial interest in patients coming through a supervised door rather than an overseas one. That does not make the regulatory summary wrong.

Bottom line

If the FDA follows the committee, a proposed rule and comment period come first, and the substances would remain unapproved drugs available only by prescription through a compounding pharmacy. Nobody knows yet whether the agency will follow it at all.